Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Biomea Fusion, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/31/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/25/2023 |
8-K
| Quarterly results |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
SC 13G
| FMR LLC reports a 14% stake in BIOMEA FUSION INC |
| 05/02/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/20/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/03/2023 |
SC 13D/A
| Cormorant Global Healthcare Master Fund, LP reports a 10.2% stake in Biomea Fusion, Inc. |
| 04/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, by and between the Company and J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein",
"Opinion of Goodwin Procter LLP",
"Biomea Fusion Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif.,- March 29, 2023 - Biomea Fusion, Inc. , a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced today that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. All of the shares of the common stock in the proposed offering are being offered by Biomea. In addition, Biomea intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to...",
"Press Release issued by the Company on March 29, 2023" |
|
| 03/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7.2% stake in Biomea Fusion, Inc. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/12/2023 |
8-K
| Investor presentation|
Docs:
|
"Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones REDWOOD CITY, Calif., Jan. 9, 2023 — Biomea Fusion, Inc. , a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Thomas Butler, Biomea Fusion's Chief Executive Officer and Chairman of the Board, will present recent progress and 2023 corporate milestones at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 from 11:15 - 11:55 am ET, and that Biomea management will hold 1x1 meetings during the conference January 9 - 11. A live webcast of the presentation will be available ...",
"Corporate Slide Presentation of Biomea Fusion, Inc., titled “JP Morgan 2023 Corporate Presentation”" |
|
| 01/04/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 12/16/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/13/2022 |
8-K
| Investor presentation |
| 11/25/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 11/25/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/25/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/18/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/14/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 09/09/2022 |
8-K
| Quarterly results |
| 08/29/2022 |
8-K
| Quarterly results |
|
|
|